Skip to main content

Blog

Catching up on What’s Happening at PPMD’S 2026 Annual Conference

...

Solid Biosciences Shares Updates on SGT-003

...

Capricor Therapeutics Shares Positive Five-Year HOPE-2 OLE Data for Deramiocel in Duchenne

...

FDA Announces Advisory Committee Meeting to Review Capricor Therapeutics’ Biologics License Application for Deramiocel

...

Avidity Biosciences Submits Biologics License Application to FDA for del-zota

...

Inside the HHS Clinical Trials Roundtable: Why Speed, Access, and Rigor Matter for the Duchenne Community

...

Massachusetts Begins Newborn Screening for Duchenne

...

PPMD Joins FDA Leadership for Rare Disease Roundtable

...

Dyne Submits BLA to FDA for z-rostudirsen (DYNE-251) in Duchenne Amenable to Exon 51 Skipping

...

Dyne Announces Phase 3 Trial of Z-Rostudirsen, Plans for Submitting Biologics License Application to FDA

...